Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
In Vitro DiagnosticsRespiratory

PUBLISHER: MarketsandMarkets | PRODUCT CODE: 1390412

Cover Image

PUBLISHER: MarketsandMarkets | PRODUCT CODE: 1390412

Respiratory Diagnostics Market by Product & Services, Test, OSA, Imaging, Molecular, Indication - Global Forecast to 2029

PUBLISHED:
PAGES: 338 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 4950
PDF (5-user License)
USD 6650
PDF (Corporate License)
USD 8150
PDF (Global License)
USD 10000

Add to Cart

Description

Table of Contents

Report Description

Scope of the Report
Years Considered for the Study2021-2029
Base Year2022
Forecast Period2023-2029
Units ConsideredValue (USD) Billion
SegmentsProduct and Service, Test Type, Disease Indication, End user, and Region
Regions coveredNorth America, Europe, APAC, LATAM, MEA

The global respiratory diagnostics market is projected to reach USD 8.2 billion by 2029 from USD 5.6 billion in 2023, at a CAGR of 6.6% during the forecast period. The growth of the respiratory diagnostics market is propelled by a combination of factors that collectively address the increasing global burden of respiratory diseases. Technological advancements, particularly in diagnostic tools and imaging techniques, have greatly improved the precision and efficiency of respiratory diagnostics, allowing for early detection and more effective management of conditions like COPD, TB, and lung cancer etc. Rising awareness among healthcare professionals and the public about the importance of early diagnosis, coupled with government-led screening programs, has contributed to a higher demand for respiratory diagnostic tests. The emergence of the COVID-19 pandemic has added a new dimension to the market, emphasizing the urgency of rapid and accurate diagnostics for respiratory infections. Changes in regulations, such as new requirements for product approval, labeling, or quality standards, can restrain the market growth.

"Instruments and Devices segment accounted for the largest share and is expected to grow at the highest rate during the forecast period."

Due to the continuous advancements in diagnostic technologies, including imaging devices, spirometers, and other respiratory diagnostic instruments. Additionally, the increasing prevalence of respiratory diseases worldwide has driven the demand for sophisticated and accurate diagnostic tools, amplifying the significance of this segment. Innovations in point-of-care testing devices and portable diagnostic instruments have further fueled the growth of the Instruments and Devices segment, enabling healthcare professionals to conduct rapid and precise respiratory assessments. Hence, the aforementioned factors are driving the growth of the respiratory diagnostics market.

"The Mechanical tests segment accounted for the largest share and is expected to grow at the highest rate during the forecast period."

Mechanical tests encompass a range of diagnostic tools, such as spirometers and peak flow meters, which play a significant role in evaluating lung capacity and airflow. The growing prevalence of respiratory disorders, coupled with the need for accurate diagnosis and monitoring, has propelled the demand for mechanical tests. Additionally, advancements in technology have enhanced the efficiency and accuracy of these tests, further driving their widespread adoption. Increasing demand for precise and comprehensive mechanical assessments of respiratory function will drive the growth of the respiratory diagnostics market.

"Asthma segment accounted for the largest share of the global respiratory diagnostics market."

The rise in environmental pollutants, changing lifestyles, and genetic factors contribute to the growing incidence of asthma, necessitating advanced diagnostic solutions. The Asthma segment encompasses a range of diagnostic modalities, including pulmonary function tests, imaging techniques, and biomarker assessments, providing a comprehensive approach to asthma diagnosis and management. The continuous research and development efforts in this segment, with a focus on personalized medicine, are driving the growth of the respiratory diagnostics market.

"Hospitals and clinics end-user segment held the largest market share growing at the highest CAGR during the forecast period of the global respiratory diagnostics market."

The rise in respiratory diseases, coupled with the growing awareness of the importance of early detection, has led to a surge in diagnostic procedures conducted in these facilities. The Hospitals and Clinics segment encompasses a wide range of diagnostic tools and services, including imaging studies, pulmonary function tests, and molecular diagnostics, providing a comprehensive approach to respiratory health assessment. By the increasing demand for respiratory diagnostic services in healthcare settings, where hospitals and clinics play a central role in disease diagnosis, management, and treatment, position this segment at the forefront of addressing the evolving challenges in respiratory diagnostics.

"North America to Witness Significant Growth From 2023 to 2029."

Respiratory diagnostics market has been segmented into five major regional segments: North America, Europe, Asia Pacific, Latin America and Middle East and Africa. In 2022, the Asia Pacific region is anticipated to exhibit the highest compound annual growth rate (CAGR) during the forecast period. However, the North American market held the largest market share of the global market. North America stands as the frontrunner in the respiratory diagnostics market, commanding the largest market share throughout the forecast period. This leadership position is attributed to several factors, including a well-established healthcare infrastructure, high prevalence of respiratory diseases, and robust research and development activities in the region. The sophisticated diagnostic technologies available, coupled with a strong emphasis on early disease detection and management, contribute to the region's dominance. Additionally, increased healthcare spending, a rising geriatric population, and growing awareness about respiratory health further propel market growth.

Breakdown of supply-side primary interviews: * By Company Type: Tier 1 - 35%, Tier 2 - 40%, and Tier 3 - 25% * By Designation: C-level - 30%, Director-level - 23%, and Others - 47% * By Region: North America - 35%, Europe - 20%, APAC - 25%, Latin America - 13%, Middle East & Africa - 7%

Some of the prominent players in the respiratory diagnostics market are Koninklijke Philips N.V. (Netherlands), BD (US), Abbott (US), Thermo Fisher Scientific Inc. (US), GE HealthCare (US), Bio-Rad Laboratories, Inc. (US), BioMerieux (France), Revvity, Inc. (US), Seegene Inc. (South Korea), Nihon Kohden Corporation (Japan), Vitalograph (UK), SDI Diagnostics (US), ResMed Inc. (US), Siemens Healthcare GmbH (Germany), Cosmed (Italy), Hologic, Inc. (US), Qiagen (Netherlands), Vyaire (US), Visby Medical, Inc (US), Briota Technologies Private Limited (India), Bird Healthcare (Australia), Lowenstein Medical Technology (Germany), ProAxsis (Northern Ireland), ndd Medical Technologies (US) and Compumedics Limited (Australia).

Research Coverage

This report studies respiratory diagnostics market based on products and services, test type, disease indication, end user, and region. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth. It analyzes the opportunities and challenges in the market and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five main regions and respective countries.

Reasons to Buy the Report

The report can help established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share. Firms purchasing the report could use one or a combination of the below-mentioned five strategies.

This report provides insights into the following pointers:

  • Analysis of key drivers (rising prevalence of respiratory diseases, Increasing incidence rate of preterm births, growing outbreaks of infectious diseases affecting the respiratory system, growing population with sleep disorders, rising R&D investments for technological advancement of medical devices), restraints (unfavorable reimbursement scenario for respiratory care diagnostics), opportunities (high respiratory diagnostics market growth opportunities in Asia Pacific and Latin America, improving POC diagnostics, growing awareness about the ill effects of untreated sleep apnea), and challenges (low awareness and lack of diagnosis of respiratory diseases) influencing the growth of respiratory diagnostics market.
  • Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and product launches in respiratory diagnostics market.
  • Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various types of respiratory diagnostics across regions.
  • Market Diversification: Exhaustive information about products, untapped regions, recent developments, and investments in respiratory diagnostics market.
  • Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in respiratory diagnostics market.
Show more
Product Code: MD 4740

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
  • 1.3 INCLUSIONS & EXCLUSIONS
  • 1.4 MARKET SCOPE
    • 1.4.1 MARKETS COVERED
    • 1.4.2 REGIONS COVERED
    • 1.4.3 YEARS CONSIDERED
    • 1.4.4 CURRENCY CONSIDERED
  • 1.5 STAKEHOLDERS
  • 1.6 SUMMARY OF CHANGES
    • 1.6.1 RECESSION IMPACT

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • FIGURE 1 RESEARCH DESIGN
    • 2.1.1 SECONDARY DATA
      • 2.1.1.1 Key data from secondary sources
    • 2.1.2 PRIMARY DATA
    • FIGURE 2 PRIMARY SOURCES
      • 2.1.2.1 Key industry insights
      • 2.1.2.2 Key data from primary sources
      • 2.1.2.3 Breakdown of primary interviews
    • FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
    • FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY END USER, DESIGNATION, AND REGION
    • FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
  • 2.2 MARKET SIZE ESTIMATION
    • FIGURE 6 SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
    • FIGURE 7 REVENUE SHARE ANALYSIS ILLUSTRATION: KONINKLIJKE PHILIPS N.V.
    • FIGURE 8 SUPPLY-SIDE ANALYSIS: RESPIRATORY DIAGNOSTICS MARKET (2022)
    • FIGURE 9 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • FIGURE 10 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
    • FIGURE 11 TOP-DOWN APPROACH
  • 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
    • FIGURE 12 MARKET DATA TRIANGULATION METHODOLOGY
  • 2.4 MARKET SHARE ESTIMATION
  • 2.5 STUDY ASSUMPTIONS
  • 2.6 RESEARCH LIMITATIONS
    • 2.6.1 METHODOLOGY-RELATED LIMITATIONS
    • 2.6.2 SCOPE-RELATED LIMITATIONS
  • 2.7 RISK ASSESSMENT
    • TABLE 1 RISK ASSESSMENT: RESPIRATORY DIAGNOSTICS MARKET
  • 2.8 IMPACT OF RECESSION ON RESPIRATORY DIAGNOSTICS MARKET

3 EXECUTIVE SUMMARY

    • FIGURE 13 RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2023 VS. 2029 (USD MILLION)
    • FIGURE 14 RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2023 VS. 2029 (USD MILLION)
    • FIGURE 15 RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2023 VS. 2029 (USD MILLION)
    • FIGURE 16 RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2023 VS. 2029 (USD MILLION)
    • FIGURE 17 GEOGRAPHICAL SNAPSHOT OF RESPIRATORY DIAGNOSTICS MARKET

4 PREMIUM INSIGHTS

  • 4.1 RESPIRATORY DIAGNOSTICS MARKET OVERVIEW
    • FIGURE 18 TECHNOLOGICAL ADVANCEMENTS AND GROWTH IN GERIATRIC POPULATION TO DRIVE MARKET
  • 4.2 GEOGRAPHICAL GROWTH OPPORTUNITIES: RESPIRATORY DIAGNOSTICS MARKET
    • FIGURE 19 NORTH AMERICA COMMANDED LARGEST MARKET SHARE IN 2022
  • 4.3 REGIONAL MIX: RESPIRATORY DIAGNOSTICS MARKET
    • FIGURE 20 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
  • 4.4 DEVELOPED VS. EMERGING ECONOMIES: RESPIRATORY DIAGNOSTICS MARKET, 2023 VS. 2029 (USD MILLION)
    • FIGURE 21 EMERGING ECONOMIES TO REGISTER HIGHER GROWTH DURING STUDY PERIOD

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 22 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES: RESPIRATORY DIAGNOSTICS MARKET
    • 5.2.1 DRIVERS
      • 5.2.1.1 Rising prevalence of respiratory diseases
        • 5.2.1.1.1 Growth in global geriatric population
    • FIGURE 23 GLOBAL GERIATRIC POPULATION, BY REGION
        • 5.2.1.1.2 Urbanization and growing pollution levels
    • FIGURE 24 PERCENTAGE OF DEATHS CAUSED BY HOUSEHOLD AND AMBIENT AIR POLLUTION, BY DISEASE (APPROXIMATELY, EVERY YEAR)
        • 5.2.1.1.3 Rising prevalence of tobacco smoking
    • TABLE 2 PREVALENCE OF LIFESTYLE DISEASES AND RELATED DEATHS
        • 5.2.1.1.4 Changing lifestyle, obesity, and physical inactivity
      • 5.2.1.2 Increasing rate of preterm births
    • TABLE 3 TOP 10 COUNTRIES WITH HIGHEST NUMBER OF PRETERM BIRTHS, 2020
    • FIGURE 25 PRETERM BIRTH BY GESTATIONAL AGE AND REGION, 2020
      • 5.2.1.3 Increasing outbreaks of infectious diseases affecting respiratory system
      • 5.2.1.4 Growing population with sleep disorders
      • 5.2.1.5 Rising R&D investments for technologically advanced medical devices
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Unfavorable reimbursement policies
      • 5.2.2.2 Availability of low-cost products from local manufacturers
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Increased market growth in Asia Pacific and Latin America
      • 5.2.3.2 Improving POC diagnostics
      • 5.2.3.3 Increasing ill effects of untreated sleep apnea
    • TABLE 4 INITIATIVES TO PROMOTE AWARENESS ABOUT ILL EFFECTS OF UNTREATED SLEEP APNEA
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Low awareness and lack of diagnosis of respiratory diseases
  • 5.3 INDUSTRY TRENDS
    • 5.3.1 RISING DEMAND FOR POINT-OF-CARE DIAGNOSTIC DEVICES
    • 5.3.2 FOCUS OF MARKET PLAYERS ON GEOGRAPHICAL EXPANSIONS
    • 5.3.3 INCREASING NUMBER OF REAGENT RENTAL AGREEMENTS
  • 5.4 SUPPLY CHAIN ANALYSIS
    • FIGURE 26 SUPPLY CHAIN ANALYSIS: RESPIRATORY DIAGNOSTICS MARKET
  • 5.5 TARIFF AND REGULATORY ANALYSIS
    • 5.5.1 REGULATORY ANALYSIS
      • 5.5.1.1 North America
        • 5.5.1.1.1 US
    • TABLE 5 US: CLASSIFICATION OF MEDICAL EQUIPMENT
    • TABLE 6 US: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
        • 5.5.1.1.2 Canada
    • TABLE 7 CANADA: LEVEL OF RISK, TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
      • 5.5.1.2 Europe
    • TABLE 8 EUROPE: LEVEL OF RISK, TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
      • 5.5.1.3 Asia Pacific
        • 5.5.1.3.1 Japan
    • TABLE 9 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
        • 5.5.1.3.2 China
    • TABLE 10 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
        • 5.5.1.3.3 India
    • 5.5.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
      • 5.5.2.1 North America
    • TABLE 11 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
      • 5.5.2.2 Europe
    • TABLE 12 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
      • 5.5.2.3 Rest of the World
    • TABLE 13 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.6 ECOSYSTEM MARKET MAP
    • FIGURE 27 ECOSYSTEM MARKET MAP: RESPIRATORY DIAGNOSTICS MARKET
  • 5.7 VALUE CHAIN ANALYSIS
    • FIGURE 28 VALUE CHAIN ANALYSIS: RESPIRATORY DIAGNOSTICS MARKET
  • 5.8 TECHNOLOGY ANALYSIS
    • 5.8.1 KEY TECHNOLOGIES
      • 5.8.1.1 Digitalization of diagnostic tests
    • 5.8.2 ADJACENT TECHNOLOGIES
      • 5.8.2.1 Rapid respiratory diagnostic kits
    • 5.8.3 COMPLEMENTARY TECHNOLOGIES
  • 5.9 PATENT ANALYSIS
    • 5.9.1 PATENT PUBLICATION TRENDS
    • FIGURE 29 PATENT PUBLICATION TRENDS, 2013-2023
    • 5.9.2 JURISDICTION AND TOP APPLICANT ANALYSIS
    • FIGURE 30 TOP APPLICANTS AND OWNERS (COMPANIES/INSTITUTIONS) FOR RESPIRATORY DIAGNOSTIC PATENTS (JANUARY 2013-NOVEMBER 2023)
    • FIGURE 31 TOP APPLICANT COUNTRIES/REGIONS FOR RESPIRATORY DIAGNOSTIC PATENTS (JANUARY 2013-NOVEMBER 2023)
  • 5.10 TRADE ANALYSIS
    • TABLE 14 TOP EXPORTERS OF RESPIRATORY DIAGNOSTICS DEVICES, 2022 (USD MILLION)
  • 5.11 CASE STUDY ANALYSIS
    • TABLE 15 MONITORING OF COPD PATIENTS AT HOME
    • TABLE 16 REPLACEMENT PATTERN OF VENTILATORS IN DEVELOPED ECONOMIES VS. EMERGING ECONOMIES
    • TABLE 17 VOLUME DATA OF VENTILATORS, ICU VENTILATORS, PORTABLE VENTILATORS, PAP DEVICES, CPAP DEVICES, BIPAP DEVICES, AND SPIROMETERS
  • 5.12 PORTER'S FIVE FORCES ANALYSIS
    • TABLE 18 PORTER'S FIVE FORCES ANALYSIS
    • 5.12.1 THREAT OF NEW ENTRANTS
    • 5.12.2 THREAT OF SUBSTITUTES
    • 5.12.3 BARGAINING POWER OF SUPPLIERS
    • 5.12.4 BARGAINING POWER OF BUYERS
    • 5.12.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.13 KEY CONFERENCES & EVENTS
    • TABLE 19 LIST OF KEY CONFERENCES & EVENTS IN 2023-2024
  • 5.14 KEY STAKEHOLDERS & BUYING CRITERIA
    • 5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • FIGURE 32 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR RESPIRATORY DIAGNOSTIC DEVICES
    • TABLE 20 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS
    • 5.14.2 BUYING CRITERIA
    • FIGURE 33 KEY BUYING CRITERIA FOR RESPIRATORY DIAGNOSTIC DEVICES
    • TABLE 21 KEY BUYING CRITERIA FOR RESPIRATORY DIAGNOSTIC DEVICES
  • 5.15 PRICING ANALYSIS
    • TABLE 22 AVERAGE SELLING PRICE OF RESPIRATORY DIAGNOSTIC DEVICES, BY PRODUCT TYPE (USD)
    • 5.15.1 AVERAGE SELLING PRICE TREND, BY REGION
  • 5.16 ADJACENT MARKETS
    • FIGURE 34 ADJACENT MARKETS OF RESPIRATORY DIAGNOSTICS MARKET
  • 5.17 UNMET NEEDS IN RESPIRATORY DIAGNOSTIC DEVICES
  • 5.18 USE OF ARTIFICIAL INTELLIGENCE IN RESPIRATORY DIAGNOSTICS MARKET
    • TABLE 23 USE OF ARTIFICIAL INTELLIGENCE IN RESPIRATORY DIAGNOSTICS MARKET
    • 5.18.1 USE OF BIG DATA AND ARTIFICIAL INTELLIGENCE IN HEALTHCARE
  • 5.19 REIMBURSEMENT SCENARIO ANALYSIS
    • TABLE 24 REIMBURSEMENT SCENARIO: RESPIRATORY DIAGNOSTICS MARKET

6 RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE

  • 6.1 INTRODUCTION
    • TABLE 25 RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021-2029 (USD MILLION)
  • 6.2 INSTRUMENTS AND DEVICES
    • 6.2.1 INCREASING PREVALENCE OF RESPIRATORY DISEASES TO DRIVE MARKET
    • TABLE 26 RESPIRATORY DIAGNOSTICS MARKET FOR INSTRUMENTS AND DEVICES, BY COUNTRY, 2021-2029 (USD MILLION)
  • 6.3 ASSAYS AND REAGENTS
    • 6.3.1 RISING DEMAND FOR RESPIRATORY DIAGNOSTIC TEST KITS TO DRIVE MARKET
    • TABLE 27 RESPIRATORY DIAGNOSTICS MARKET FOR ASSAYS AND REAGENTS, BY COUNTRY, 2021-2029 (USD MILLION)
  • 6.4 SERVICES AND SOFTWARE
    • 6.4.1 INTRODUCTION TO ADVANCED AND AUTOMATED TECHNOLOGIES TO DRIVE MARKET
    • TABLE 28 RESPIRATORY DIAGNOSTICS MARKET FOR SERVICES & SOFTWARE, BY COUNTRY, 2021-2029 (USD MILLION)

7 RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE

  • 7.1 INTRODUCTION
    • TABLE 29 RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2029 (USD MILLION)
  • 7.2 MECHANICAL TESTS
    • TABLE 30 RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 31 RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021-2029 (USD MILLION)
    • 7.2.1 PULMONARY FUNCTION TESTS
    • TABLE 32 PULMONARY FUNCTION TESTS MARKET, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 33 PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021-2029 (USD MILLION)
    • 7.2.2 SPIROMETRY
      • 7.2.2.1 Spirometry to dominate pulmonary function tests segment during forecast period
    • TABLE 34 SPIROMETRY TESTS MARKET, BY COUNTRY, 2021-2029 (USD MILLION)
    • 7.2.3 PEAK FLOW TESTS
      • 7.2.3.1 Precise measurements from peak flow tests to help focus on effective treatment plans
    • TABLE 35 PEAK FLOW TESTS MARKET, BY COUNTRY, 2021-2029 (USD MILLION)
    • 7.2.4 OBSTRUCTIVE SLEEP APNEA TESTS
      • 7.2.4.1 Increased focus on diagnosis of sleep apnea at early stages to drive segment
    • TABLE 36 OBSTRUCTIVE SLEEP APNEA TESTS MARKET, BY COUNTRY, 2021-2029 (USD MILLION)
    • 7.2.5 OTHER MECHANICAL TESTS
    • TABLE 37 OTHER MECHANICAL TESTS MARKET, BY COUNTRY, 2021-2029 (USD MILLION)
  • 7.3 IMAGING TESTS
    • TABLE 38 RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 39 RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021-2029 (USD MILLION)
    • 7.3.1 X-RAY
      • 7.3.1.1 Increased investments in advanced radiographic technologies for superior lung imaging to drive segment
    • TABLE 40 X-RAY MARKET, BY COUNTRY, 2021-2029 (USD MILLION)
    • 7.3.2 COMPUTED TOMOGRAPHY
      • 7.3.2.1 Growing focus on manufacturing high-resolution CT imaging for comprehensive respiratory assessments to drive segment
    • TABLE 41 COMPUTED TOMOGRAPHY MARKET, BY COUNTRY, 2021-2029 (USD MILLION)
    • 7.3.3 MAGNETIC RESONANCE IMAGING
      • 7.3.3.1 Rising investments in AI-enhanced MRI analysis for precise respiratory assessment to drive segment
    • TABLE 42 MAGNETIC RESONANCE IMAGING MARKET, BY COUNTRY, 2021-2029 (USD MILLION)
    • 7.3.4 POSITRON EMISSION TOMOGRAPHY
      • 7.3.4.1 Increased focus on effective treatment and management of lung cancer to drive segment
    • TABLE 43 POSITRON EMISSION TOMOGRAPHY MARKET, BY COUNTRY, 2021-2029 (USD MILLION)
    • 7.3.5 OTHER IMAGING TESTS
    • TABLE 44 OTHER IMAGING TESTS MARKET, BY COUNTRY, 2021-2029 (USD MILLION)
  • 7.4 TRADITIONAL DIAGNOSTIC TESTS
    • TABLE 45 RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 46 RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021-2029 (USD MILLION)
    • 7.4.1 IMMUNODIAGNOSTICS
      • 7.4.1.1 Increased focus on rapid disease diagnosis to drive segment
    • TABLE 47 IMMUNODIAGNOSTICS MARKET, BY COUNTRY, 2021-2029 (USD MILLION)
    • 7.4.2 BIOCHEMICAL CHARACTERIZATION
      • 7.4.2.1 Rising number of collaborations among biochemical laboratories for developing advanced diagnostics to drive segment
    • TABLE 48 BIOCHEMICAL CHARACTERIZATION MARKET, BY COUNTRY, 2021-2029 (USD MILLION)
    • 7.4.3 MICROSCOPY
      • 7.4.3.1 Lack of sensitivity toward emerging diseases and potential virus bioterrorism to limit market
    • TABLE 49 MICROSCOPY MARKET, BY COUNTRY, 2021-2029 (USD MILLION)
  • 7.5 MOLECULAR DIAGNOSTIC TESTS
    • TABLE 50 RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTIC TESTS, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 51 RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTIC TESTS, BY TYPE, 2021-2029 (USD MILLION)
    • 7.5.1 PCR
      • 7.5.1.1 Development of portable, real-time PCR machines and assays to drive segment
    • TABLE 52 PCR MARKET, BY COUNTRY, 2021-2029 (USD MILLION)
    • 7.5.2 NUCLEIC ACID AMPLIFICATION
      • 7.5.2.1 Growing focus on automated nucleic acid amplification processes to drive segment
    • TABLE 53 NUCLEIC ACID AMPLIFICATION MARKET, BY COUNTRY, 2021-2029 (USD MILLION)
    • 7.5.3 IN SITU HYBRIDIZATION
      • 7.5.3.1 Increased adoption of automated technologies for streamlined respiratory testing to drive segment
    • TABLE 54 IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2021-2029 (USD MILLION)
    • 7.5.4 DNA SEQUENCING AND NEXT-GENERATION SEQUENCING
      • 7.5.4.1 Rising number of research activities on sequencing-based biomarkers to drive segment
    • TABLE 55 DNA SEQUENCING AND NEXT GENERATION SEQUENCING MARKET, BY COUNTRY, 2021-2029 (USD MILLION)
    • 7.5.5 MICROARRAYS
      • 7.5.5.1 Easy and effective detection of genetic signatures across multiple genes to drive segment
    • TABLE 56 MICROARRAYS MARKET, BY COUNTRY, 2021-2029 (USD MILLION)
    • 7.5.6 OTHER MOLECULAR DIAGNOSTIC TESTS
    • TABLE 57 OTHER MOLECULAR DIAGNOSTIC TESTS MARKET, BY COUNTRY, 2021-2029 (USD MILLION)

8 RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION

  • 8.1 INTRODUCTION
    • TABLE 58 RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021-2029 (USD MILLION)
  • 8.2 TUBERCULOSIS
    • 8.2.1 INCREASING EARLY SCREENING PROGRAMS AND FUNDS BY GOVERNMENT TO DRIVE MARKET
    • TABLE 59 RESPIRATORY DIAGNOSTICS MARKET FOR TUBERCULOSIS, BY COUNTRY, 2021-2029 (USD MILLION)
  • 8.3 ASTHMA
    • 8.3.1 INCREASING AIR POLLUTION AND GROWING USE OF TOBACCO-BASED PRODUCTS TO DRIVE MARKET
    • TABLE 60 RESPIRATORY DIAGNOSTICS MARKET FOR ASTHMA, BY COUNTRY, 2021-2029 (USD MILLION)
  • 8.4 LUNG CANCER
    • 8.4.1 INCREASING NUMBER OF TOBACCO CONSUMERS TO DRIVE MARKET
    • TABLE 61 RESPIRATORY DIAGNOSTICS MARKET FOR LUNG CANCER, BY COUNTRY, 2021-2029 (USD MILLION)
  • 8.5 CHRONIC OBSTRUCTIVE PULMONARY DISEASE
    • 8.5.1 INCREASED INVESTMENT IN RESEARCH GRANTS FOR NOVEL BIOMARKERS AND DIAGNOSTIC TECHNOLOGIES TO DRIVE MARKET
    • TABLE 62 RESPIRATORY DIAGNOSTICS MARKET FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE, BY COUNTRY, 2021-2029 (USD MILLION)
  • 8.6 OTHER RESPIRATORY DISEASES
    • TABLE 63 RESPIRATORY DIAGNOSTICS MARKET FOR OTHER RESPIRATORY DISEASES, BY COUNTRY, 2021-2029 (USD MILLION)

9 RESPIRATORY DIAGNOSTICS MARKET, BY END USER

  • 9.1 INTRODUCTION
    • TABLE 64 RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021-2029 (USD MILLION)
  • 9.2 HOSPITALS AND CLINICS
    • 9.2.1 HOSPITALS AND CLINICS SEGMENT TO COMMAND LARGEST MARKET SHARE DURING STUDY PERIOD
    • TABLE 65 RESPIRATORY DIAGNOSTICS MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2021-2029 (USD MILLION)
  • 9.3 DIAGNOSTIC LABORATORIES
    • 9.3.1 EASY AND AFFORDABLE TESTING PROCESSES WITH TIMELY AND ACCURATE RESULTS TO DRIVE MARKET
    • TABLE 66 RESPIRATORY DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2021-2029 (USD MILLION)
  • 9.4 OTHER END USERS
    • TABLE 67 RESPIRATORY DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2021-2029 (USD MILLION)

10 RESPIRATORY DIAGNOSTICS MARKET, BY REGION

  • 10.1 INTRODUCTION
    • FIGURE 35 RESPIRATORY DIAGNOSTICS MARKET REGIONAL SNAPSHOT
    • TABLE 68 RESPIRATORY DIAGNOSTICS MARKET, BY REGION, 2021-2029 (USD MILLION)
  • 10.2 NORTH AMERICA
    • FIGURE 36 NORTH AMERICA: RESPIRATORY DIAGNOSTICS MARKET SNAPSHOT
    • TABLE 69 NORTH AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 70 NORTH AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021-2029 (USD MILLION)
    • TABLE 71 NORTH AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2029 (USD MILLION)
    • TABLE 72 NORTH AMERICA: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 73 NORTH AMERICA: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 74 NORTH AMERICA: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 75 NORTH AMERICA: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 76 NORTH AMERICA: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 77 NORTH AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021-2029 (USD MILLION)
    • TABLE 78 NORTH AMERICA RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021-2029 (USD MILLION)
    • 10.2.1 NORTH AMERICA: RECESSION IMPACT
    • 10.2.2 US
      • 10.2.2.1 US to dominate North American respiratory diagnostics market during forecast period
    • TABLE 79 US: KEY MACROINDICATORS
    • TABLE 80 US: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021-2029 (USD MILLION)
    • TABLE 81 US: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2029 (USD MILLION)
    • TABLE 82 US: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 83 US: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 84 US: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 85 US: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 86 US: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 87 US: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021-2029 (USD MILLION)
    • TABLE 88 US: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021-2029 (USD MILLION)
    • 10.2.3 CANADA
      • 10.2.3.1 Growing geriatric population and increasing awareness about early diagnosis of respiratory diseases to drive market
    • TABLE 89 CANADA: COPD AND ASTHMA STATISTICS (2019 VS. 2020)
    • TABLE 90 CANADA: KEY MACROINDICATORS
    • TABLE 91 CANADA: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021-2029 (USD MILLION)
    • TABLE 92 CANADA: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2029 (USD MILLION)
    • TABLE 93 CANADA: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 94 CANADA: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 95 CANADA: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 96 CANADA: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 97 CANADA: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 98 CANADA: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021-2029 (USD MILLION)
    • TABLE 99 CANADA: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021-2029 (USD MILLION)
  • 10.3 EUROPE
    • TABLE 100 EUROPE: RESPIRATORY DIAGNOSTICS MARKET, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 101 EUROPE: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021-2029 (USD MILLION)
    • TABLE 102 EUROPE: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2029 (USD MILLION)
    • TABLE 103 EUROPE: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 104 EUROPE: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 105 EUROPE: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 106 EUROPE: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 107 EUROPE: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 108 EUROPE: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021-2029 (USD MILLION)
    • TABLE 109 EUROPE: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021-2029 (USD MILLION)
    • 10.3.1 EUROPE: RECESSION IMPACT
    • 10.3.2 GERMANY
      • 10.3.2.1 Increasing public healthcare expenditure to drive market
    • TABLE 110 GERMANY: KEY MACROINDICATORS
    • TABLE 111 GERMANY: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021-2029 (USD MILLION)
    • TABLE 112 GERMANY: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2029 (USD MILLION)
    • TABLE 113 GERMANY: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 114 GERMANY: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 115 GERMANY: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 116 GERMANY: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 117 GERMANY: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 118 GERMANY: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021-2029 (USD MILLION)
    • TABLE 119 GERMANY: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021-2029 (USD MILLION)
    • 10.3.3 FRANCE
      • 10.3.3.1 Increasing prevalence of COPD and growing geriatric population to drive market
    • TABLE 120 FRANCE: KEY MACROINDICATORS
    • TABLE 121 FRANCE: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021-2029 (USD MILLION)
    • TABLE 122 FRANCE: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2029 (USD MILLION)
    • TABLE 123 FRANCE: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 124 FRANCE: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 125 FRANCE: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 126 FRANCE: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 127 FRANCE: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 128 FRANCE: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021-2029 (USD MILLION)
    • TABLE 129 FRANCE: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021-2029 (USD MILLION)
    • 10.3.4 UK
      • 10.3.4.1 Rising number of hospitals and increasing government funding to drive market
    • TABLE 130 UK: KEY MACROINDICATORS
    • TABLE 131 UK: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021-2029 (USD MILLION)
    • TABLE 132 UK: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2029 (USD MILLION)
    • TABLE 133 UK: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 134 UK: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 135 UK: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 136 UK: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 137 UK: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 138 UK: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021-2029 (USD MILLION)
    • TABLE 139 UK: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021-2029 (USD MILLION)
    • 10.3.5 ITALY
      • 10.3.5.1 Unfavorable reforms and reduction in healthcare expenditure by government to limit market
    • TABLE 140 ITALY: KEY MACROINDICATORS
    • TABLE 141 ITALY: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021-2029 (USD MILLION)
    • TABLE 142 ITALY: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2029 (USD MILLION)
    • TABLE 143 ITALY: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 144 ITALY: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 145 ITALY: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 146 ITALY: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 147 ITALY: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 148 ITALY: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021-2029 (USD MILLION)
    • TABLE 149 ITALY: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021-2029 (USD MILLION)
    • 10.3.6 SPAIN
      • 10.3.6.1 Increasing healthcare spending and growing demand for home care services to drive market
    • TABLE 150 SPAIN: KEY MACROINDICATORS
    • TABLE 151 SPAIN: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021-2029 (USD MILLION)
    • TABLE 152 SPAIN: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2029 (USD MILLION)
    • TABLE 153 SPAIN: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 154 SPAIN: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 155 SPAIN: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 156 SPAIN: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 157 SPAIN: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 158 SPAIN: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021-2029 (USD MILLION)
    • TABLE 159 SPAIN: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021-2029 (USD MILLION)
    • 10.3.7 REST OF EUROPE
    • TABLE 160 REST OF EUROPE: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021-2029 (USD MILLION)
    • TABLE 161 REST OF EUROPE: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2029 (USD MILLION)
    • TABLE 162 REST OF EUROPE: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 163 REST OF EUROPE: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 164 REST OF EUROPE: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 165 REST OF EUROPE: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 166 REST OF EUROPE: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 167 REST OF EUROPE: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021-2029 (USD MILLION)
    • TABLE 168 REST OF EUROPE: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021-2029 (USD MILLION)
  • 10.4 ASIA PACIFIC
    • FIGURE 37 ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET SNAPSHOT
    • TABLE 169 ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 170 ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021-2029 (USD MILLION)
    • TABLE 171 ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2029 (USD MILLION)
    • TABLE 172 ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 173 ASIA PACIFIC: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 174 ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 175 ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 176 ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 177 ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021-2029 (USD MILLION)
    • TABLE 178 ASIA PACIFIC RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021-2029 (USD MILLION)
    • 10.4.1 ASIA PACIFIC: RECESSION IMPACT
    • 10.4.2 JAPAN
      • 10.4.2.1 Availability of universal healthcare reimbursement policy and growth in geriatric population to drive market
    • TABLE 179 JAPAN: KEY MACROINDICATORS
    • TABLE 180 JAPAN: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021-2029 (USD MILLION)
    • TABLE 181 JAPAN: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2029 (USD MILLION)
    • TABLE 182 JAPAN: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 183 JAPAN: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 184 JAPAN: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 185 JAPAN: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 186 JAPAN: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 187 JAPAN: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021-2029 (USD MILLION)
    • TABLE 188 JAPAN RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021-2029 (USD MILLION)
    • 10.4.3 CHINA
      • 10.4.3.1 Modern healthcare systems and improved reimbursement policies to drive market
    • TABLE 189 CHINA: KEY MACROINDICATORS
    • TABLE 190 CHINA: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021-2029 (USD MILLION)
    • TABLE 191 CHINA: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2029 (USD MILLION)
    • TABLE 192 CHINA: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 193 CHINA: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 194 CHINA: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 195 CHINA: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 196 CHINA: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 197 CHINA: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021-2029 (USD MILLION)
    • TABLE 198 CHINA: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021-2029 (USD MILLION)
    • 10.4.4 INDIA
      • 10.4.4.1 Large patient population and availability of skilled medical professionals to drive market
    • TABLE 199 INDIA: KEY MACROINDICATORS
    • TABLE 200 INDIA: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021-2029 (USD MILLION)
    • TABLE 201 INDIA: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2029 (USD MILLION)
    • TABLE 202 INDIA: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 203 INDIA: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 204 INDIA: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 205 INDIA: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 206 INDIA: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 207 INDIA: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021-2029 (USD MILLION)
    • TABLE 208 INDIA: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021-2029 (USD MILLION)
    • 10.4.5 AUSTRALIA
      • 10.4.5.1 Growing prevalence of chronic lung diseases to drive market
    • TABLE 209 AUSTRALIA: KEY MACROINDICATORS
    • TABLE 210 AUSTRALIA: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021-2029 (USD MILLION)
    • TABLE 211 AUSTRALIA: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2029 (USD MILLION)
    • TABLE 212 AUSTRALIA: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 213 AUSTRALIA: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 214 AUSTRALIA: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 215 AUSTRALIA: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 216 AUSTRALIA: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 217 AUSTRALIA: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021-2029 (USD MILLION)
    • TABLE 218 AUSTRALIA RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021-2029 (USD MILLION)
    • 10.4.6 SOUTH KOREA
      • 10.4.6.1 Increasing geriatric population and rising disposable income to drive market
    • TABLE 219 SOUTH KOREA: KEY MACROINDICATORS
    • TABLE 220 SOUTH KOREA: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021-2029 (USD MILLION)
    • TABLE 221 SOUTH KOREA: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2029 (USD MILLION)
    • TABLE 222 SOUTH KOREA: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 223 SOUTH KOREA: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 224 SOUTH KOREA: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 225 SOUTH KOREA: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 226 SOUTH KOREA: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 227 SOUTH KOREA: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021-2029 (USD MILLION)
    • TABLE 228 SOUTH KOREA RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021-2029 (USD MILLION)
    • 10.4.7 REST OF ASIA PACIFIC
    • TABLE 229 REST OF ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021-2029 (USD MILLION)
    • TABLE 230 REST OF ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2029 (USD MILLION)
    • TABLE 231 REST OF ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 232 REST OF ASIA PACIFIC: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 233 REST OF ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 234 REST OF ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 235 REST OF ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 236 REST OF ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021-2029 (USD MILLION)
    • TABLE 237 REST OF ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021-2029 (USD MILLION)
  • 10.5 LATIN AMERICA
    • TABLE 238 LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 239 LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021-2029 (USD MILLION)
    • TABLE 240 LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2029 (USD MILLION)
    • TABLE 241 LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 242 LATIN AMERICA: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 243 LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 244 LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 245 LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 246 LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021-2029 (USD MILLION)
    • TABLE 247 LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021-2029 (USD MILLION)
    • 10.5.1 LATIN AMERICA: RECESSION IMPACT
    • 10.5.2 BRAZIL
      • 10.5.2.1 Favorable healthcare initiatives by government to drive market
    • TABLE 248 BRAZIL: KEY MACROINDICATORS
    • TABLE 249 BRAZIL: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021-2029 (USD MILLION)
    • TABLE 250 BRAZIL: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2029 (USD MILLION)
    • TABLE 251 BRAZIL: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 252 BRAZIL: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 253 BRAZIL: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 254 BRAZIL: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 255 BRAZIL: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 256 BRAZIL: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021-2029 (USD MILLION)
    • TABLE 257 BRAZIL: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021-2029 (USD MILLION)
    • 10.5.3 MEXICO
      • 10.5.3.1 Rising obesity rates and improving medical tourism to drive market
    • TABLE 258 MEXICO: KEY MACROINDICATORS
    • TABLE 259 MEXICO: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021-2029 (USD MILLION)
    • TABLE 260 MEXICO: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2029 (USD MILLION)
    • TABLE 261 MEXICO: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 262 MEXICO: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 263 MEXICO: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 264 MEXICO: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 265 MEXICO: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 266 MEXICO: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021-2029 (USD MILLION)
    • TABLE 267 MEXICO: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021-2029 (USD MILLION)
    • 10.5.4 REST OF LATIN AMERICA
    • TABLE 268 REST OF LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021-2029 (USD MILLION)
    • TABLE 269 REST OF LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2029 (USD MILLION)
    • TABLE 270 REST OF LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 271 REST OF LATIN AMERICA: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 272 REST OF LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 273 REST OF LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 274 REST OF LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 275 REST OF LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021-2029 (USD MILLION)
    • TABLE 276 REST OF LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021-2029 (USD MILLION)
  • 10.6 MIDDLE EAST & AFRICA
    • 10.6.1 GROWING PATIENT POPULATION AND INCREASING PENETRATION OF PRIVATE HEALTH INSURANCE COMPANIES TO DRIVE MARKET
    • TABLE 277 MIDDLE EAST & AFRICA: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021-2029 (USD MILLION)
    • TABLE 278 MIDDLE EAST & AFRICA: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2029 (USD MILLION)
    • TABLE 279 MIDDLE EAST & AFRICA: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 280 MIDDLE EAST & AFRICA: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 281 MIDDLE EAST & AFRICA: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 282 MIDDLE EAST & AFRICA: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 283 MIDDLE EAST & AFRICA: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 284 MIDDLE EAST & AFRICA: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021-2029 (USD MILLION)
    • TABLE 285 MIDDLE EAST & AFRICA RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021-2029 (USD MILLION)
    • 10.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT

11 COMPETITIVE LANDSCAPE

  • 11.1 OVERVIEW
  • 11.2 KEY STRATEGIES/RIGHT TO WIN
    • TABLE 286 KEY STRATEGIES ADOPTED BY MAJOR PLAYERS IN RESPIRATORY DIAGNOSTICS MARKET
  • 11.3 REVENUE SHARE ANALYSIS
    • FIGURE 38 RESPIRATORY DIAGNOSTICS REVENUE SHARE ANALYSIS FOR MECHANICAL, TRADITIONAL, AND MOLECULAR TESTS, BY KEY PLAYER, 2018-2022 (USD MILLION)
    • FIGURE 39 RESPIRATORY DIAGNOSTICS REVENUE SHARE ANALYSIS FOR IMAGING TESTS, BY KEY PLAYER, 2018-2022 (USD MILLION)
  • 11.4 MARKET SHARE ANALYSIS
    • FIGURE 40 RESPIRATORY DIAGNOSTICS MARKET SHARE FOR MECHANICAL, TRADITIONAL, AND MOLECULAR TESTS, BY KEY PLAYER, 2022
    • FIGURE 41 RESPIRATORY DIAGNOSTICS MARKET SHARE ANALYSIS FOR IMAGING TESTS, BY KEY PLAYER, 2022
  • 11.5 COMPANY EVALUATION MATRIX
    • 11.5.1 STARS
    • 11.5.2 EMERGING LEADERS
    • 11.5.3 PERVASIVE PLAYERS
    • 11.5.4 PARTICIPANTS
    • FIGURE 42 COMPANY EVALUATION MATRIX, 2022
    • 11.5.5 COMPANY FOOTPRINT
    • TABLE 287 PRODUCT AND SERVICE FOOTPRINT
    • TABLE 288 TEST TYPE FOOTPRINT
    • TABLE 289 END USER FOOTPRINT
    • TABLE 290 REGIONAL FOOTPRINT
    • TABLE 291 OVERALL COMPANY FOOTPRINT
  • 11.6 START-UP/SME EVALUATION MATRIX
    • 11.6.1 PROGRESSIVE COMPANIES
    • 11.6.2 RESPONSIVE COMPANIES
    • 11.6.3 DYNAMIC COMPANIES
    • 11.6.4 STARTING BLOCKS
    • FIGURE 43 START-UP/SME EVALUATION MATRIX, 2022
    • 11.6.5 COMPETITIVE BENCHMARKING
  • 11.7 COMPETITIVE SCENARIOS AND TRENDS
    • 11.7.1 KEY PRODUCT LAUNCHES
    • TABLE 292 KEY PRODUCT LAUNCHES, 2021-2023
    • 11.7.2 KEY DEALS
    • TABLE 293 KEY DEALS, 2021-2023
    • 11.7.3 OTHER KEY DEVELOPMENTS
    • TABLE 294 OTHER KEY DEVELOPMENTS, 2021-2023

12 COMPANY PROFILES

  • 12.1 KEY PLAYERS
  • (Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)**
    • 12.1.1 KONINKLIJKE PHILIPS N.V.
    • TABLE 295 KONINKLIJKE PHILIPS N.V.: COMPANY OVERVIEW
    • FIGURE 44 KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT (2022)
    • 12.1.2 BECTON, DICKINSON AND COMPANY
    • TABLE 296 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW
    • FIGURE 45 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2022)
    • 12.1.3 ABBOTT
    • TABLE 297 ABBOTT: COMPANY OVERVIEW
    • FIGURE 46 ABBOTT: COMPANY SNAPSHOT (2022)
    • 12.1.4 THERMO FISHER SCIENTIFIC INC.
    • TABLE 298 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
    • FIGURE 47 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022)
    • 12.1.5 GE HEALTHCARE
    • TABLE 299 GE HEALTHCARE: COMPANY OVERVIEW
    • FIGURE 48 GE HEALTHCARE: COMPANY SNAPSHOT (2022)
    • 12.1.6 BIO-RAD LABORATORIES, INC.
    • TABLE 300 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW
    • FIGURE 49 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2022)
    • 12.1.7 BIOMERIEUX
    • TABLE 301 BIOMERIEUX: COMPANY OVERVIEW
    • FIGURE 50 BIOMERIEUX: COMPANY SNAPSHOT (2022)
    • 12.1.8 REVVITY, INC.
    • TABLE 302 REVVITY, INC.: COMPANY OVERVIEW
    • FIGURE 51 PERKINELMER INC.: COMPANY SNAPSHOT (2022)
    • 12.1.9 SEEGENE INC.
    • TABLE 303 SEEGENE INC.: COMPANY OVERVIEW
    • FIGURE 52 SEEGENE INC.: COMPANY SNAPSHOT (2022)
    • 12.1.10 NIHON KOHDEN CORPORATION
    • TABLE 304 NIHON KOHDEN CORPORATION: COMPANY OVERVIEW
    • FIGURE 53 NIHON KOHDEN CORPORATION: COMPANY SNAPSHOT (2022)
    • 12.1.11 VITALOGRAPH
    • TABLE 305 VITALOGRAPH: COMPANY OVERVIEW
    • 12.1.12 SDI DIAGNOSTICS
    • TABLE 306 SDI DIAGNOSTICS: COMPANY OVERVIEW
    • 12.1.13 RESMED
    • TABLE 307 RESMED: COMPANY OVERVIEW
    • FIGURE 54 RESMED: COMPANY SNAPSHOT (2022)
    • 12.1.14 SIEMENS HEALTHCARE GMBH
    • TABLE 308 SIEMENS HEALTHCARE GMBH: COMPANY OVERVIEW
    • FIGURE 55 SIEMENS HEALTHCARE GMBH: COMPANY SNAPSHOT (2022)
    • 12.1.15 COSMED SRL
    • TABLE 309 COSMED SRL: COMPANY OVERVIEW
    • 12.1.16 HOLOGIC, INC.
    • TABLE 310 HOLOGIC, INC.: COMPANY OVERVIEW
    • FIGURE 56 HOLOGIC, INC.: COMPANY SNAPSHOT (2022)
    • 12.1.17 QIAGEN
    • TABLE 311 QIAGEN: COMPANY OVERVIEW
    • FIGURE 57 QIAGEN: COMPANY SNAPSHOT (2022)
  • *Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.
  • 12.2 OTHER PLAYERS
    • 12.2.1 VYAIRE MEDICAL, INC.
    • 12.2.2 VISBY MEDICAL, INC.
    • 12.2.3 BRIOTA TECHNOLOGIES PVT. LTD.
    • 12.2.4 BIRD HEALTHCARE
    • 12.2.5 LOWENSTEIN MEDICAL TECHNOLOGY GMBH
    • 12.2.6 PROAXSIS
    • 12.2.7 NDD MEDICAL TECHNOLOGIES
    • 12.2.8 COMPUMEDICS LIMITED

13 APPENDIX

  • 13.1 DISCUSSION GUIDE
  • 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.3 CUSTOMIZATION OPTIONS
  • 13.4 RELATED REPORTS
  • 13.5 AUTHOR DETAILS
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!